Hypertension Is Associated with Marked Alterations in Sphingolipid Biology: A Potential Role for Ceramide by Spijkers, Léon J. A. et al.
Hypertension Is Associated with Marked Alterations in
Sphingolipid Biology: A Potential Role for Ceramide
Le ´on J. A. Spijkers
1, Rob F. P. van den Akker
1, Ben J. A. Janssen
3, Jacques J. Debets
3,J oG .R .D eM e y
3,
Erik S. G. Stroes
2, Bert-Jan H. van den Born
2, Dayanjan S. Wijesinghe
4, Charles E. Chalfant
4, Luke
MacAleese
5, Gert B. Eijkel
5, Ron M. A. Heeren
5, Astrid E. Alewijnse
1, Stephan L. M. Peters
1*
1Department of Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands, 2Vascular Medicine, Academic Medical Center,
Amsterdam, The Netherlands, 3Department of Pharmacology and Toxicology, Maastricht University, Maastricht, The Netherlands, 4Department of Biochemistry, Virginia
Commonwealth University, Richmond, Virginia, United States of America, 5FOM Institute for Atomic and Molecular Physics, Amsterdam, The Netherlands
Abstract
Background: Hypertension is, amongst others, characterized by endothelial dysfunction and vascular remodeling. As
sphingolipids have been implicated in both the regulation of vascular contractility and growth, we investigated whether
sphingolipid biology is altered in hypertension and whether this is reflected in altered vascular function.
Methods and Findings: In isolated carotid arteries from spontaneously hypertensive rats (SHR) and normotensive Wistar-
Kyoto (WKY) rats, shifting the ceramide/S1P ratio towards ceramide dominance by administration of a sphingosine kinase
inhibitor (dimethylsphingosine) or exogenous application of sphingomyelinase, induced marked endothelium-dependent
contractions in SHR vessels (DMS: 1.460.4 and SMase: 2.160.1 mN/mm; n=10), that were virtually absent in WKY vessels
(DMS: 0.060.0 and SMase: 0.660.1 mN/mm; n=9, p,0.05). Imaging mass spectrometry and immunohistochemistry
indicated that these contractions were most likely mediated by ceramide and dependent on iPLA2, cyclooxygenase-1 and
thromboxane synthase. Expression levels of these enzymes were higher in SHR vessels. In concurrence, infusion of
dimethylsphingosine caused a marked rise in blood pressure in anesthetized SHR (4264%; n=7), but not in WKY
(212610%; n=6). Lipidomics analysis by mass spectrometry, revealed elevated levels of ceramide in arterial tissue of SHR
compared to WKY (691642 vs. 419627 pmol, n=3–5 respectively, p,0.05). These pronounced alterations in SHR
sphingolipid biology are also reflected in increased plasma ceramide levels (513619 pmol WKY vs. 645625 pmol SHR,
n=6–12, p,0.05). Interestingly, we observed similar increases in ceramide levels (correlating with hypertension grade) in
plasma from humans with essential hypertension (18568 pmol vs. 252623 pmol; n=18 normotensive vs. n=19
hypertensive patients, p,0.05).
Conclusions: Hypertension is associated with marked alterations in vascular sphingolipid biology such as elevated ceramide
levels and signaling, that contribute to increased vascular tone.
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Introduction
Hypertension is a major risk factor for cardiac, cerebrovascular
and renal disease. It is associated with increased vasomotor tone,
decreased vasodilator potential and inward remodeling of blood
vessels. The presence of vasomotor imbalance in essential
hypertension is partly mediated by decreased nitric oxide
bioavailability and elevated release of endothelium-derived
contractile factor (EDCF) as characteristics of endothelial
dysfunction, and impaired smooth muscle cell responsiveness
towards relaxing factors [1,2]. Regulation of vascular reactivity
and cellular growth have been shown to be partially mediated by
an intrinsic network of bioactive lipids classified as sphingolipids,
of which sphingomyelin is abundantly present in virtually all cells.
Sphingomyelin is an ubiquitous membrane (sphingo)phospho-
lipid that may serve as a substrate for sphingomyelinases for the
production of ceramide [3]. Ceramide can be further converted
into ceramide-1-phosphate (C1P), glucosylceramide or sphingosine
by phosphorylation, glucosylation or deacylation, respectively.
Subsequently, sphingosine can be phosphorylated by sphingosine
kinases to yield sphingosine-1-phosphate (S1P), which can target
five G-protein coupled S1P receptors (S1P1–5), of which S1P1–3 are
expressed in the cardiovascular system [4]. S1P receptor activation
induces proliferation of many cell types including vascular cells [5].
Conversely, sphingosine and ceramide, the precursors of S1P,
have growth-inhibiting and pro-apoptotic actions [6]. Because of
these opposing actions of sphingomyelin metabolites, this system is
also referred to as the ceramide/S1P rheostat [7]. In addition to
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sphingolipids are involved in the regulation of vascular tone, for
instance by regulating nitric oxide and EDHF-mediated relaxing
responses in different types of blood vessels [8–10].
Because sphingolipids are involved in the regulation of both
vascular growth and vascular tone, we hypothesized that in
essential hypertension, sphingolipid ratios are altered, resulting in
an altered vasomotor function. Here we show that 1) Elevation of
vascular ceramide leads to vasoconstriction due to increased TXA2
release in vessels of SHR. 2) These constrictions are only observed
in vessels of SHR due to increased expression of enzymes involved
in thromboxane A2 synthesis. 3) That basal ceramide levels are
elevated in both SHR and humans with hypertension.
Results
Modulation of sphingolipid metabolism induces
transient constrictions in isolated SHR carotid artery
Contractile responses of isolated carotid artery segments to K
+
(100 mmol/L) and phenylephrine (Phe; 0.3 mmol/L) were slightly
reduced in vessels of SHR compared to WKY (Table 1).
Endothelium-dependent relaxation to methacholine (MCh;
10 mmol/L) during Phe pre-contraction was impaired in SHR,
reflecting endothelial dysfunction (maximal relaxation: 9161%
WKY vs 5061% SHR, n=10, p,0.05, Fig. 1A and Table 1).
Incubation of the carotid artery segments with the sphingosine
kinase inhibitor dimethylsphingosine (DMS; 10 mmol/L) or
dihydrosphingosine (DHS; 30 mmol/L, data not shown) induced
a marked transient contraction in SHR vessels, which was absent
in age-matched WKY rats (Fig. 1A). In addition, exogenously
applied neutral sphingomyelinase (SMase; 0.1 U/mL) evoked
similar contractile responses in SHR vessels that were much less
pronounced in vessels of WKY (Fig. 1A). When DMS and SMase
were applied simultaneously, contraction was slightly higher, but
not synergistically elevated (Fig. 1B), suggesting a similar
mechanism of action. Importantly, contractions induced by
DMS or SMase in the SHR carotid artery were completely
abolished by mechanical removal of the endothelium. In contrast,
the nitric oxide synthase inhibitor L-NAME significantly increased
DMS-induced and SMase-induced contractions (Fig. 1C).
Sphingomyelinase-induced contractions require
cyclooxygenase-1 and involve elevated thromboxane
A2 production
The non-selective cyclooxygenase (COX) inhibitor indometha-
cin (10 mmol/L) and the COX-1 selective inhibitor SC560
(1 mmol/L) entirely prevented SMase-induced contraction in
SHR carotid artery (Fig. 2), while the COX-2 selective inhibitor
NS398 (1 mmol/L) was without effect. Applying higher concen-
trations of NS398 resulted in decrease contractile responses,
however, at these concentrations NS398 is reported to non-
specifically inhibit COX [11]. Since COX products include
contractile prostaglandins and thromboxane, we applied the
thromboxane/prostaglandin (TP) receptor antagonist SQ29548,
which concentration-dependently inhibited SMase-induced con-
tractions. Furthermore, the thromboxane synthase (TXAS)
inhibitor Ozagrel concentration-dependently inhibited vascular
contraction (Fig. 2). In order to investigate whether the sensitivity
of agonist-induced TP receptor activation was different for SHR
and WKY carotid arteries, we generated concentration-response
curves for the thromboxane analogue U46619, which was not
different between SHR and WKY (Fig. S1). Immunohistochemical
quantification of COX-1 and TXAS expression showed that
COX-1 was elevated in SHR smooth muscle cells compared to
WKY (Fig. 3A). TXAS expression in SHR was significantly
elevated compared to WKY in endothelium (Fig. 3B).
Calcium-independent phospholipase A2 is the source of
arachidonic acid in SMase-induced contractions
To investigate which enzyme was mainly responsible for
generating the COX substrate arachidonic acid, several phospho-
lipase A2 (PLA2) inhibitors were applied. The individual or
combined addition of inhibitors of cytosolic PLA2 (AACOF3;
30 mmol/L) or secretory PLA2 (Luffariellolide; 2 mmol/L) to
SMase-induced contractions were without effect. However, the
calcium-independent PLA2 (iPLA2)-specific inhibitor Bromoenol
lactone (BEL, 25 mmol/L) significantly inhibited SMase-induced
contractions (Fig. 2). In line with this, immunohistochemical
quantification indicated increased expression of iPLA2 in the
endothelium and a decreased expression in smooth muscle cells of
SHR. Accordingly, the ratio of EC/VSMC iPLA2 expression was
markedly shifted towards the endothelium in SHR compared to
WKY vessels (Fig. 3C). Imaging mass spectrometry and experi-
ments with SMaseD (which generates C1P directly from
sphingomyelin) revealed that ceramide (and not C1P) is most
likely responsible for iPLA2 activation (Fig. S2, Fig. S3).
In vivo administration of DMS results in a marked rise of
blood pressure in SHR but not WKY
To investigate whether sphingolipid modulation also differen-
tially affects blood pressure in vivo, DMS was applied i.v. to
isoflurane-anesthetized SHR and WKY. Arterial blood pressure
was measured, as well as common carotid blood flow using a
transit time flow probe. Baseline hemodynamic values that were
obtained after stabilization of the preparation are shown in
Table 1. Mean arterial pressure was substantially higher in SHR
than in WKY. In SHR, application of DMS, but not vehicle,
resulted in a significant increase in mean arterial pressure (Fig. 4),
accompanied by a further rise in carotid artery resistance and
slightly decreased heart rate (Fig. S4). In WKY however, DMS
had little effect on blood pressure. The heart rate was not
significantly different between SHR and WKY after DMS
administration.
Ceramide levels are increased in arterial tissue of SHR
Mass spectrometric analysis [12] revealed significantly increased
levels of total ceramide in arterial tissue (aorta) of hypertensive rats
compared to normotensive rats. No significant changes in total
sphingomyelin, C1P, sphingosine and S1P were observed (Fig. 5A).
The significant increase in total ceramide was mainly due to
increased C16:0, C18:0 and C24:1 ceramides (Fig. S5).
Plasma ceramide levels are increased in both
hypertensive rats and humans
Mass spectrometric lipidomics analysis revealed increased total
ceramide levels and slightly increased sphingosine levels in blood
plasma from SHR (Fig. 5B). The increased total ceramide levels
were mainly due to increases in C16:0, C22:0 C24:1 and C24:0
ceramides (Fig. S5).
In plasma of humans with stage 2+3 essential hypertension,
ceramide levels were significantly higher compared to healthy
normotensive controls (243.2623.5 pmol vs 183.2611.1 pmol
respectively, n=18–19, p,0.05; Fig. 6A). Moreover, ceramide
levels correlated with increasing severity of hypertension, with
ceramide levels in humans with stage 1 hypertension being
intermediate of those from normotensives and stage 2–3
hypertensives (Fig. 6B). The distribution pattern of sphingolipids
Sphingolipids in Essential Hypertension
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Increases in C24:1 and C24:0 ceramides mainly accounted for the
observed increase in total plasma ceramide in hypertensive
humans (Fig. S5). In contrast to significantly altered hypertensive
patient plasma S1P levels compared to normotensive patients
(37.061.8 pmol vs 32.061.2 pmol respectively, p,0.05), no
significant changes in plasma S1P in rats were seen
(355.6617.1 pmol vs 312.1616.7 pmol respectively, p.0.05).
Whether this reflects species differences or differences in sample
collection remains to be determined [13]. In respect of
Figure 1. DMS-induced and SMase-induced contraction in SHR and WKY carotid artery. A) Original tracing of rat carotid artery segments
exposed to DMS (10 mmol/L) or SMase (0.1 U/mL). Note reduced relaxing response to MCh (10 mmol/L) in SHR, indicating pronounced endothelial
dysfunction. B) Maximal contractile responses to DMS and/or SMase in intact WKY and SHR vessels and C) SHR vessel responses in the presence of
L-NAME or endothelium-denudation (-EC). Phenylephrine (Phe), methacholine (MCh), dimethylsphingosine (DMS), sphingomyelinase C (SMase),
N
v-Nitro-L-arginine methyl ester (L-NAME). Data presented as mean 6 SEM, n=5–6, (*) p,0.05.
doi:10.1371/journal.pone.0021817.g001
Sphingolipids in Essential Hypertension
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in both human and rat samples with the given sample size,
although a trend of decreased C1P plasma levels was observed in
human hypertensives (29.061.7 pmol normotensives vs
26.061.9 pmol hypertensives, p.0.05).
Discussion
Previous studies from our group and others have shown that
sphingolipids are involved in the regulation of the release or action
of endothelium-derived relaxing factors (NO and EDHF)
[8,14,15]. Here we show for the first time that 1) Elevation of
vascular ceramide leads to vasoconstriction due to increased TXA2
release in vessels of SHR. 2) These constrictions are only observed
in vessels of SHR due to increased expression of enzymes involved
in thromboxane A2 synthesis. 3) That basal ceramide levels are
elevated in both SHR and humans with hypertension.
Altered sphingolipid biology in hypertension
Because sphingolipids have vasoactive properties and play a
pivotal role in cellular growth, we hypothesized that the
sphingolipid system is involved in hypertension, a condition
associated with altered vascular contractility and remodeling.
Alterations in sphingolipid biology in hypertension were exempli-
fied by the fact that pharmacological modulation of vascular
sphingolipid composition, by means of the application of the
sphingosine kinase inhibitors DMS or DHS, induced pronounced
transient contractile responses in isolated carotid arteries from
SHR but not from WKY. In analogy to sphingosine kinase
inhibition, also the exogenous application of SMase induced
contractions in carotid arteries from SHR, but only minor
responses in arteries from WKY.
Mechanism of SMase and DMS-induced contractions
Simultaneous application of DMS and SMase induced stronger
arterial contractions than either component alone, but without
signs of synergy, suggesting common pathways. Both modulators
likely induce an accumulation of ceramide as a shared mechanism,
as has been shown for SMase [16] and DMS in several cellular
systems [17,18]. Interestingly, the transient contractions induced
by both DMS and SMase proved to be endothelium-dependent
since mechanical removal of the endothelium abolished the
contractions. In contrast, pre-incubation with the NO synthase
inhibitor L-NAME augmented these contractions, indicating that
the contractions are not due to a reduced NO bioavailability.
This endothelium dependency presents similarities to the
‘‘classical’’ endothelium-derived contractile factor (EDCF) de-
scribed in the vasculature of SHR and human patients with
Table 1. General characteristics of anaesthetized SHR and
WKY rats and ex vivo carotid artery segments.
Parameters WKY SHR
n1 0 1 0
Weight, gram 482683 6 0 66*
MAP, mmHg (under isoflurane) 71639 5 66*
Blood flow, mL/min (systolic, carotid a.) 28631 8 62*
Heart rate, BPM (under isoflurane) 343610 30965*
Lumen Ø, mm (segment at 90 mmHg) 11196122 106969*
Constriction, mN/mm (3
rd K
+) 4.160.2 3.560.1 *
Relaxation, %Phe preconstriction 91615 0 61*
Data expressed as mean 6SEM, (*) p,0.05.
doi:10.1371/journal.pone.0021817.t001
Figure 2. Characterization of SMase-induced contraction in SHR carotid artery. SMase-induced contraction, in absence and presence of the
non-specific COX inhibitor indomethacin (Indo), COX-1 specific inhibitor SC560, COX-2 specific inhibitor NS398, the PLA2 inhibitors AACOF3 (cPLA2)
and Luffariellolide (Luff; sPLA2), Bromoenol lactone (BEL; iPLA2), the thromboxane synthase inhibitor Ozagrel and the thromboxane receptor
antagonist SQ29548 (SQ29). Data presented as mean 6 SEM, n=4–6, (*) p,0.05 compared to control SMase.
doi:10.1371/journal.pone.0021817.g002
Sphingolipids in Essential Hypertension
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acetylcholine in both SHR and human essential hypertension
involve the release of a COX-1-derived EDCF. The prostanoids
PGH2,P G I 2 and thromboxane A2 have been suggested as the
EDCFs responsible for increased vascular tone in hypertension
[2].
In the present study, both DMS- and SMase-induced contrac-
tions in SHR carotid arteries could be decreased by selective COX-
1 inhibition but not by inhibition of COX-2. Furthermore, the fact
that TXAS inhibition attenuated SMase-induced contractions,
suggests that under our experimental conditions the contractions
are caused by the generationof TXA2. Although the involvement of
PGI2 is unlikely, its contribution cannot be fully excluded [21]. The
prominentrole ofTXA2 isfurthersupportedbytheobservationthat
SMase-induced contractions were concentration-dependently
inhibited by the TP-receptor antagonist SQ29548. The possibility
that SHRthromboxane signalingis potentiated dueto increased TP
receptor expression or affinity in VSMCs is unlikely because the
concentration-response-curves for the thromboxane analogue
U46619 were comparable in SHR and WKY arteries. This is also
in line with other studies, showing no TP receptor expression
changes in SHR [22]. Thus, it seems that modulation of endothelial
sphingolipid composition by ceramide elevation induces a COX-1-
dependent release of TXA2 in vessels from SHR. Immunohisto-
chemical analysis indicated elevated COX-1 expression in SHR
vascular smooth muscle cells, which is supportedby findings of Ge et
al. [23], that smooth muscle cells from SHR aorta display elevated
COX-1 mRNA expression. In addition to COX-1, we observed
Figure 3. Immunohistochemistry of relevant proteins in SHR carotid artery. A) Immunohistochemical staining (left, typical staining images;
2006 magnification) and quantification (right) of SHR or WKY carotid artery segments depicting cell nuclei staining (blue), with/without the von
Willebrand Factor (vWF) endothelium marker (green) and cyclooxygenase-1 (COX-1; red). B) thromboxane synthase (TXAS; red) and C) calcium-
independent phospholipase A2 (iPLA2; red). Please note the increased EC/VSMC iPLA2 expression ratio in SHR. Data presented as mean 6 SEM, n=5–
6, (*) p,0.05, scale bars 100 mm.
doi:10.1371/journal.pone.0021817.g003
Sphingolipids in Essential Hypertension
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previously shown by Tang et al. [22], at the mRNA level. The
increased TXAS protein expression reached statistical significance
in SHR carotid artery endothelium.
The link between sphingolipid metabolism and
eicosanoid synthesis
In the process of EDCF generation, substrate delivery to COX-
1 depends primarily on PLA2 activity (for recent reviews see
Vanhoutte et al. [24] and Feletou et al. [2]). Three PLA2 subtypes
have been described thus far. While secretory PLA2 (sPLA2) and
cytosolic PLA2 (cPLA2) require calcium for activation, calcium-
independent PLA2 (iPLA2), located in both cytosolic and
membrane fractions, does not require Ca
2+ directly for catalytic
activity [25]. Importantly, sphingolipids have previously been
implicated in PLA2 activation; both ceramide and C1P have been
shown to activate sPLA2 and/or cPLA2 in vitro [26,27]. However,
in the present study both single and combined addition of non-
specific cPLA2 and sPLA2 inhibitors did not affect SMase-induced
contractions. The iPLA2-specific inhibitor BEL nevertheless, was
effective in this respect, suggesting that endogenous iPLA2 may
contribute to the contractile phenotype of arteries in SHR. This is
also in line with the recent findings of Wong et al. [28], and is
further supported by our immunohistochemical finding that the
endothelium in SHR (compared to WKY) expresses significantly
more iPLA2, while levels appeared lower in the smooth muscle
layer of the artery segments. This results in a remarkable increase
in the ratio of endothelium/smooth muscle iPLA2 expression in
the carotid arteries of SHR. That ceramides are able to activate
iPLA2 is supported by findings of Gong et al [29]. In the present
study imaging mass spectrometry and experiments with SMaseD
revealed that ceramide (and not C1P) is most likely responsible for
iPLA2 activation (Fig. S2, Fig. S3).
Pathophysiological role of sphingolipids in hypertension-
associated endothelial dysfunction
The aforementioned findings indicate that ceramide participates
in the prominent role of thromboxane A2 in the SHR. Our
lipidomics (LC-MS) analysis revealed that in arterial tissue of SHR
ceramide levels were significantly higher when compared to
normotensive WKY rats. It is tempting to speculate that the
elevated basal arterial ceramide levels observed in our study
contribute to endothelial dysfunction in SHR since these may lead
to constitutive TXA2 production. In this regard, it is noteworthy
that thromboxane receptor antagonism completely restored
endothelial function in SHR. Furthermore, increased ceramide
levels in hypertension may possibly be derived from elevated
angiotensin II type 2 receptor signaling, which has been linked to
ceramide production (for review see Berry et al. [30]) Results from
another study by Johns et al. indicated decreased levels of ceramide
in smooth muscle cells of SHR [31]. This discrepancy may be due
to the fact that we determined ceramide levels directly in freshly
Figure 4. In vivo effects of DMS infusion in SHR and WKY. Rats
were treated with bolus injection and subsequent infusion of DMS
(3 mg/kg followed by 6 mg/kg/hr) or vehicle (0.75% rat serum albumin
in saline) during recording of mean arterial pressure (MAP). Data
expressed as mean maximal change from baseline 6 SEM, n=6–8,
(*) p,0.05.
doi:10.1371/journal.pone.0021817.g004
Figure 5. Liquid-chromatography-mass spectrometry measure-
ments of total sphingolipid content. Content was measured in A)
SHR and WKY aorta homogenate and B) blood plasma. Data presented
as mean 6 SEM, n=3–5 (for 6–10 pooled aortas) and 6–12 (for plasma
samples), (*) p,0.05.
doi:10.1371/journal.pone.0021817.g005
Sphingolipids in Essential Hypertension
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muscle cells between passages 3 and 12, which is known to induce
phenotypic changes including changes in sphingolipid signaling
[32].
The physiological relevance of ceramide-induced thromboxane
A2 release (Fig. S6) is reflected by the observation that in vivo
infusion of DMS resulted in increased arterial resistance and blood
pressure in SHR, but not WKY rats. This marked blood pressure
elevation was probably not due to cardiac effects of DMS since we
observed a concomitant decrease in heart rate. The rise in
systemic blood pressure indicates that, in addition to large conduit
vessels such as the carotid artery, also resistance vessels of SHR are
sensitive to DMS. Although the contractions to DMS in isolated
carotid arteries were not due to inhibition of NO production, as
indicated by the augmented contractile response in the presence of
L-NAME, a possible inhibitory effect of DMS on NO production
in vivo in other vascular beds cannot be excluded. The DMS-
induced pressor response clearly emphasizes the importance of
altered sphingolipid biology in vascular tone and blood pressure
regulation in vivo in hypertensive rats.
Interestingly, the altered sphingolipid biology and elevated
arterial ceramide levels in the vasculature of SHR are also
reflected in increased plasma ceramide levels. Moreover, analysis
of plasma from hypertensive- and normotensive humans revealed
similar elevations in ceramide levels in patients with essential
hypertension. Ceramide plasma levels showed a stepwise increase
with increasing severity of hypertension, with ceramide levels in
patients with stage 1 hypertension being intermediate of those
from normotensives and stage 2–3 hypertensives. This implies that
similar pathophysiological mechanisms in human hypertension
may contribute to increased vascular tone and endothelial
dysfunction. Of interest, very recently, a genetic analysis by
Fenger et al. also suggested the involvement of the ceramide/S1P
rheostat in the blood pressure regulation in human hypertension
on a genetic basis [33].
In summary, we provide new insight in the pathophysiological
role of sphingolipids in endothelial function and hypertension.
We demonstrate that elevation of vascular ceramide in SHR
induces a marked endothelium-dependent release of TXA2 that
may contribute to endothelial dysfunction in hypertension. A
prerequisite for this contractile response to ceramide is the
increased arterial expression of enzymes involved in TXA2
synthesis as observed in vessels from hypertensive animals.
Moreover, basal ceramide levels are increased in both SHR
and humans with hypertension. The present study does not allow
us to draw conclusions on causality. Since the development of
hypertension in SHR precedes the development of endothelial
dysfunction it is unlikely that the alterations in sphingolipid levels
are the primary causative factor of hypertension. Nevertheless,
both our in vitro and in vivo data clearly demonstrate that these
alterations in sphingolipid biology can contribute to an increased
vascular tone. Further research of the role of sphingolipids in the
pathophysiology of human essential hypertension is therefore
warranted.
Materials and Methods
Ethics statement
Written informed consent was obtained from all participants,
and the study was approved by the local Research Ethics
Committee of the Academic Medical Center.
The experiments involving animals in this study followed a
protocol approved by the Animal Ethical Committee of the
University of Amsterdam (DFC101766) and Maastricht University
(2008-139), The Netherlands, in accordance with EU regulation
on the care and use of laboratory animals.
Human subjects
Blood plasma was obtained from otherwise healthy age-
matched treatment-naı ¨ve patients with stage 1 hypertension
(n=12) or stage 2 and 3 hypertension (n=19) and normotensive
controls (n=18). Patient characteristics are summarized in table 2.
Blood pressure was measured three times following current
guideline recommendations with an aneroid sphygmomanometer.
The average of the last two blood pressure recordings was taken
for analysis. Patients with confirmed or suspected of secondary
hypertension, pregnant women and patients aged ,18 years and
patients with (a history of) alcohol abuse were excluded from
participation.
Figure 6. Liquid-chromatography-mass spectrometry measure-
ments of sphingolipid content in human blood plasma. A)
Quantification of total sphingolipid pools in human plasma. Human
samples were collected from normotensive controls (BP,140/
90 mmHg) and from patients with stage 2 and 3 hypertension
(BP$160/100). B) Total plasma ceramide levels in normotensives
compared to stage 1 hypertensives (BP 140–159/90–99 mmHg) and
stage 2+3 hypertensives. (Data presented as mean 6 SEM, n=18 for
normotensive controls n=12 for patients with stage 1 hypertension,
n=19 for stage 2+3 hypertension. (*) p,0.05.
doi:10.1371/journal.pone.0021817.g006
Sphingolipids in Essential Hypertension
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Adult six month old male Spontaneously Hypertensive rats
(SHR) and Wistar Kyoto rats (WKY) were purchased from Charles
River (Maastricht, The Netherlands). Rats were anaesthetized by
i.p. injection of 75 mg/kg pentobarbital (O.B.G., Utrecht, The
Netherlands). Heparin (750 IU, Leo Pharma B.V., Weesp, The
Netherlands) was injected i.p. to prevent blood coagulation and
thrombocyte-derived sphingosine-1-phosphate release. After tissue
isolation, the animals were euthanized by exsanguination.
Arterial preparation and isometric force recording
Carotid artery segments were isolated form 6 months old SHR
and WKY rats and mounted into a wire myograph for isometric
force measurements as described by Mulders et al. [9] (see
Supporting Information S1). The sphingosine kinase inhibitor
DMS (10 mmol/L) and the exogenous enzyme SMase (0.1 U/mL;
from Staphylococcus aureus) or SMaseD (20 mL/OD280:0.4; from
Staphylococcus aureus) were applied to segments to measure
alterations in vasomotor tone within one hour. Inhibitors or
antagonists were administered 30 min prior to these agents. In
some experiments, the thromboxane/prostanoid receptor agonist
U46619 was applied in half-log concentration increments.
Immunohistochemistry
Enzyme expression in carotid artery segments of 6 months old
WKY and SHR were quantified using a custom protocol
developed in collaboration with Nikon Instruments Europe BV
on unprocessed images (see Supporting Information S1).
In vivo DMS administration
In vivo effects of DMS in isoflurane-anesthetized SHR and WKY
were investigated by i.v. infusion (3 mg/kg, based on a pilot dose
finding). Blood pressure, heart rate and carotid artery blood flow
were recorded (see Supporting Information S1).
Liquid chromatography - mass spectrometry of blood
plasma and aorta
Blood plasma and aortic tissue from 6 months old SHR and
WKY was isolated (Table 1). In addition, we assessed circulating
sphingolipids in blood plasma obtained from otherwise healthy age-
matched treatment naı ¨ve patients with stage 1 hypertension (n=12)
or stage 2 and 3 hypertension (n=19) and normotensive controls
(n=18). Baseline characteristics according to blood pressure
category are depicted in table 2. All samples were processed
according to an established protocol as published by Merrill et al.
[34] and Wijesinghe et al. [12] (see Supporting Information S1).
Statistical data analysis
The isometric tension measurements in carotid artery segments
are presented as mean 6SEM with ‘n’ being the number of
individual rats. Peak contraction values (relative tension, mN/mm)
during the experiments were gathered and expressed in column
graphs. Column statistics were performed by one-way ANOVA
including Dunnett’s multiple comparisons test (95% confidence
interval) with DMS or SMase values as control. The SMase
controls were the same group of data for all appropriate figures.
For protein quantification by IHC and lipid content quantification
by LC-MS, Student’s t-test was performed to compare single
conditions between SHR and WKY or normotensive versus
hypertensive subjects. Data measured in vivo were expressed as
relative percentage and compared using one-way ANOVA
including Tukey’s multiple comparison test. All statistical analyses
were performed using Prism (GraphPad Prism Software, San
Diego, CA, USA). Values of p,0.05 were considered to be
statistically significant.
Supporting Information
Figure S1 Concentration-response curve of the throm-
boxane analogue U46619 in SHR and WKY carotid
artery. Data presented as mean 6 SEM, n=4–6.
(TIF)
Figure S2 Sphingomyelinase D-induced contractions in
SHR carotid artery. Quantification of SMaseD-induced con-
tractions in SHR carotid artery, which was lower in WKY and
comparable to SMaseC. Data presented as mean 6 SEM, n=2–4.
(TIF)
Figure S3 Mass spectrometry imaging of lipids involved
in SMase-induced contraction in SHR carotid artery. A)
High resolution total ion count image of SHR carotid artery sample
(left, bottom scale bar 100 mm) and image of increased mass counts
corresponding to treatment with SMase (depiction of SMase-treated
segment total ion count minus untreated count; right image; blue)
showing highest changes in luminal side of blood vessel (endothelial
area). B) Discriminant analysis of untreated and SMase-treated tissue
categories: spectra are grouped per tissue and both tissue categories
are separated along the discriminant function. Projection of mass
spectra of standards (dots) on discriminant function (standards plotted
above DA zero correspond with elevated presence after SMase
treatment). C) Plot of the loadings for each mass channel in the
direction of main separation between tissue groups (i.e. first DA
function), showing masses (deviating from zero) that were elevated
(top) or decreased (bottom) after SMase treatment. Sphingomyelinase
C (SMase), non-treated (NT), ceramide-1- phosphate (C1P),
sphingosine-1-phosphate (S1P).
(TIF)
Figure S4 In vivo effects of DMS infusion in SHR and
WKY. Rats were treated with bolus injection and subsequent
infusion of DMS (3 mg/kg followed by 6 mg/kg/hr) or vehicle
(0.75% rat serum albumin in saline) during recording of A) carotid
artery systolic blood flow (Peak flow) and B) heart rate (HR). Data
expressed as mean maximal change from baseline 6 SEM, n=6–8,
(*) p,0.05.
(TIF)
Table 2. Patient characteristics.
Parameters Normotensive Stage 1 HT Stage 2 and 3 HT
n1 8 1 2 1 9
Age, years 44.162.5 44.162.8 47.462.6
MAP, mmHg 91.761.9 108.461.3 * 131.0616.6 *#
Systolic BP, mmHg 12162 14363* 1 7 1 66* #
Diastolic BP, mmHg 77629 1 61* 1 1 1 63* #
Male, n (%) 7 (39) 9 (75) 9 (47)
Black, n (%) 9 (50) 5 (42) 7 (37)
BMI, kg/m2 27.361.3 26.060.9 26.860.9
Diabetes, n (%) 0 (0) 0 (0) 1 (5)
Current smoking, n (%) 2 (11) 1 (8) 4 (21)
Mean arterial pressure (MAP), body mass index (BMI), blood pressure (BP). Data
expressed as mean 6SEM or percentage of total (%), (*) p,0.05 vs
normotensive subjects, and (#)p ,0.05 vs Stage 1 hypertensives (HT).
doi:10.1371/journal.pone.0021817.t002
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21817Figure S5 Ceramide subspecies in human and rat
tissue. A) Plasma spectrum of measured ceramide subspecies in rat
(SHR vs WKY) and normotensive vs. hypertensive patients. B) Rat aorta
homogenate spectrum of ceramide subspecies. n=6–19, (*) p,0.05.
(TIF)
Figure S6 Potential mechanism of sphingolipid-medi-
ated release of thromboxane A2 in SHR carotid artery.
Accumulation of ceramide by the sphingolipid modulators SMase
and DMS induces thromboxane A2 production in an iPLA2, COX-
1 and TXAS-mediated pathway. Upregulated enzyme expression
or lipid levels in SHR carotid arteries indicated by white arrows.
(TIF)
Supporting Information S1
(DOC)
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